STAR SPORTS MED (01609) recommends adopting the 2026 share incentive plan.
Tianxing Medical (01609) announced that on August 3, 2026, the Board of Directors has resolved to recommend the adoption of the 2026 Share Incentive Plan. The purpose of the Share Incentive Plan is to: (i) promote the company's long-term sustainable development and the achievement of performance goals; (ii) attract and retain qualified individuals who contribute significantly to the company's long-term growth and success, and to recognize and reward their past contributions to the Group; (iii) closely align the interests of the incentive recipients with those of shareholders, investors, and the company, enhance corporate cohesion, and maximize the value of the company; (iv) improve the company's long-term incentive mechanisms.
STAR SPORTS MED (01609) announced that on August 3, 2026, the board of directors has resolved to propose the adoption of the 2026 Share Incentive Plan. The purposes of the Share Incentive Plan are: (i) to promote the company's long-term sustainable development and achievement of performance goals; (ii) to attract and retain qualified individuals who make significant contributions to the company's long-term growth and success, as well as to recognize and reward their past contributions to the Group; (iii) to closely align the interests of the incentivized individuals with those of shareholders, investors, and the company, thereby enhancing corporate cohesion and maximizing company value; (iv) to improve the company's long-term incentive mechanism.
Related Articles

ALPHAMAB-B(09966): JSKN033 has received approval from CDE to conduct a Phase III clinical study for the treatment of cervical cancer.

Hunan Warrant Pharmaceutical (688799.SH): Ferrous Succinate Tablets and others are expected to be selected for national centralized drug procurement.

US Stock Market Move | Alibaba Group Holding Limited Sponsored ADR (BABA.US) surged over 4% after the release of Q&A 3.8-MAX.
ALPHAMAB-B(09966): JSKN033 has received approval from CDE to conduct a Phase III clinical study for the treatment of cervical cancer.

Hunan Warrant Pharmaceutical (688799.SH): Ferrous Succinate Tablets and others are expected to be selected for national centralized drug procurement.

US Stock Market Move | Alibaba Group Holding Limited Sponsored ADR (BABA.US) surged over 4% after the release of Q&A 3.8-MAX.

RECOMMEND





